Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

REVEALED: Alkermes plc | Rare Historical Photos

Alkermes Strikes $2.1 Billion Avadel Deal, Gains Access To Narcolepsy Drug Lumryz

On Wednesday, Alkermes plc (NASDAQ:ALKS) agreed to acquire Avadel Pharmaceuticals plc (NASDAQ:AVDL) for up to $20 per share in cash, which values Avadel at approximately $2.1 billion.

Benzinga

Top 3 Biotech Stocks to Consider for March Profits

The biotech sector’s growth prospects look promising thanks to the growing use of cutting-edge technologies in healthcare and the rising popularity of personalized medicines. Therefore, it could be wise to buy fundamentally strong biotech stocks Shionogi (SGIOY), Alkermes (ALKS), and Incyte (INCY) for March profits. Read more.

StockNews.com

Analyzing 3 Biotech Stocks for 2024 Gain Potential

With technology revolutionizing drug discovery, the biotech sector thrives on innovation and breakthrough therapies. Hence, let's delve into and analyze the gain potential of fundamentally strong biotech stocks Amgen (AMGN), Alkermes (ALKS), and Vertex Pharmaceuticals (VRTX). Read more….

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 Biotech Stocks Signaling Buy Opportunities

The biotech industry is well-positioned to generate returns amid breakthrough developments and the growing prevalence of chronic diseases. Given the solid long-term prospects of the industry, fundamentally sound biotech stocks Entrada Therapeutics (TRDA), Alkermes (ALKS) and Amgen (AMGN) could be ideal buys for steady gains. Read on.

StockNews.com

3 A-Rated Biotech Stocks for Your 2024 Portfolio

Inelastic demand for healthcare products and services and the increasing government initiatives around the world are expected to boost the biotech industry. Therefore, it could be wise to buy fundamentally strong biotech stocks Entrada Therapeutics (TRDA), Corcept Therapeutics (CORT), and Alkermes (ALKS) this year. Read more.

StockNews.com

Exploring the Upside Potential of 3 Biotech Stocks

Given the breakthrough developments, government support, and rising need to treat chronic diseases, the biotech industry is well-positioned to grow steadily. So, it could be wise to invest in quality biotech stocks Alkermes (ALKS), Amgen (AMGN) and Incyte (INCY). Read on….

StockNews.com

3 Best Biotech Stocks for Growth in 2023

The biotech industry is well-positioned for solid growth due to the growing demand for high-quality treatments for chronic diseases and an aging population. Therefore, it could be wise to invest in fundamentally strong biotech stocks Jazz Pharmaceuticals (JAZZ), Alkermes (ALKS), and Gilead Sciences (GILD), given their solid growth prospects. Read…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 Biotech Stocks to Buy This Month and Beyond

Owing to the critical medical needs, the lookout for new technologies to deal with future advancements is at its peak. Breakthrough innovations, revolutionary treatments, and a booming industry align to make biotech stocks a potential goldmine for savvy investors. Therefore, it could be wise to invest in quality biotech stocks…

StockNews.com

3 Biotech Stocks With Strong Value in August

The biotech industry is ascending with growing R&D initiatives, an upsurge in personalized medicine, and enhanced drug formulations, coupled with the incorporation of technological advancements. So, it seems wise to invest in discounted biotech stocks Vertex Pharmaceuticals (VRTX), Jazz Pharmaceuticals (JAZZ), and Alkermes (ALKS) this month. Keep reading….

StockNews.com

3 Biotech Stocks to Acquire in July

With the surge in new drug formulations, the growing prominence of personalized medicine, and favorable government initiatives, the biotech industry is set for significant growth this year and beyond. Thus, it could be wise to invest in fundamentally sound biotech stocks Biogen (BIIB), Alkermes (ALKS), and Theratechnologies (THTX) this month.…

StockNews.com

3 Biotech Stocks With Some Major Value in Them

The worldwide need for healthcare and biotech products is experiencing a steady upsurge fueled by various factors, such as a heightened emphasis on personalized medicine. Therefore, it could be wise to explore three quality biotech stocks, Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS), with significant value in them. Read…

StockNews.com

3 Biotech Stocks Every Investor Wants

Given inelastic demand, rapid breakthroughs, and government initiatives, the biotech industry looks well-positioned to thrive. So, quality biotech stocks Gilead Sciences (GILD), Biogen (BIIB), and Alkermes (ALKS) could be worth owning. Read on.

StockNews.com

3 Value Stocks Investors Want

Strong recent economic data and still-elevated inflation are expected to keep the Fed on track for another interest rate hike next month. With the stock market likely to remain volatile amid rising interest rates and other macro uncertainties, fundamentally sound stocks Astellas (ALPMY), Alkermes (ALKS), and AstroNova (ALOT), trading at…

StockNews.com

3 Biotech Stocks to Buy Now

The biotech industry is well-positioned to grow, given the inelastic demand, rapid advancements, and government initiatives. So, quality biotech stocks Biogen (BIIB), Alkermes (ALKS), and Vanda (VNDA) could be worth owning. Read on.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

Healthy Profits: Keep an Eye on These 2 Buy-Rated Biotech Stocks in May

The biotech industry should thrive amid breakthrough developments and increasing investments this year. Therefore, fundamentally strong biotech stocks, Alkermes (ALKS) and Nippon Shinyaku (NPPNY) might be ideal buys. Read more.

Benzinga

Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen

Alkermes plc (NASDAQ:ALKS) commenced binding arbitration proceedings regarding two license agreements with Janssen Pharmaceutica N.V., a subsidiary of Johnson & Johnson (NYSE:JNJ). Under these agreements, Janssen received access and rights to Alkermes' small particle pharmaceutical compound technology, known as NanoCrystal Technology, enabling several products. Janssen partially terminated the agreements in the U.S., effective as of…

Benzinga

Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer

Alkermes plc (NASDAQ: ALKS)

Benzinga

Why Are Alkermes Shares Trading Higher Today?

Alkermes plc's (NASDAQ: ALKS)

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Alkermes Schizophrenia Med Shows Lower Mean Weight Gain In Early Illness With Schizophrenia

Alkermes plc's (NASDAQ: ALKS) ENLIGHTEN-Early Phase 3b study of Lybalvi (olanzapine & samidorphan)

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Vertex Pharmaceuticals Incorporated

65 stories

CORT

58 stories

Jazz Pharmaceuticals plc

44 stories

ALOT

43 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.